Genmab A/S
GMAB· Nasdaq
GMABGenmab A/S
Source filing unavailable
| Metric | Q2 2025 | Q2 2024 |
|---|---|---|
| Revenue | $925.00M | $779.00M |
| Net Income | $336.00M | $203.00M |
| EPS Diluted | $5.42 | $3.13 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Genmab A/S · CIK 1434265 · Engraved from SEC EDGAR
